60 Degrees Pharmaceuticals, Inc.(SXTP)Earnings, Financials & Key Ratios
SXTP•NASDAQ
$1.66
$941067 mkt cap·Price updated May 6, 2026
About60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.Show more
- Revenue$608K+139.6%
- EBITDA-$10M-91.0%
- Net Income-$8M-111.0%
- EPS (Diluted)-18.55-1852.6%
- Gross Margin36.67%+142.1%
- EBITDA Margin-1588.48%+20.3%
- Operating Margin-1598.97%+21.3%
- Net Margin-1308.01%+11.9%
- ROE-181.58%-131.4%
- ROIC-276%+70.3%
- Debt/Equity0.04+9.5%
- Interest Coverage-1227.87-54370.0%
SXTP Key Insights
60 Degrees Pharmaceuticals, Inc. (SXTP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 88.5% through buybacks
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SXTP Price & Volume
60 Degrees Pharmaceuticals, Inc. (SXTP) stock price & volume — 10-year historical chart
Loading chart...
SXTP Growth Metrics
60 Degrees Pharmaceuticals, Inc. (SXTP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-19.4%
TTM135.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1.47%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-127.71%
Return on Capital
10 Years-117.74%
5 Years-117.74%
3 Years-159.43%
Last Year-214.68%
SXTP Peer Comparison
60 Degrees Pharmaceuticals, Inc. (SXTP) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AEYE | 95.09M | 7.66 | -30.64 | 14.52% | -7.63% | -47.8% | 0.15 | |
 MTNB | 4.01M | 0.68 | -0.14 | -100% | -270.65% | 0.38 | ||
 GERN | 999.8M | 1.56 | -12 | 138.83% | -35.48% | -28.9% | 1.11 | |
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 AMRN | 309.92M | 14.90 | -8.28 | -6.55% | -15.64% | -7.34% | 0.03 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 |
Compare SXTP vs Peers
60 Degrees Pharmaceuticals, Inc. (SXTP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SXTP Income Statement
60 Degrees Pharmaceuticals, Inc. (SXTP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 2.18M | 1.16M | 223.21K | 253.57K | 607.57K | 963.53K |
| Revenue Growth % | - | -46.81% | -80.76% | 13.6% | 139.61% | 135.78% |
| Cost of Goods Sold | 702.99K | 850.74K | 432.37K | 474.55K | 384.76K | 779.09K |
| COGS % of Revenue | 32.23% | 73.32% | 193.71% | 187.15% | 63.33% | - |
| Gross Profit | 1.48M▲ 0% | 309.6K▼ 79.1% | -209.16K▼ 167.6% | -220.98K▼ 5.6% | 222.81K▲ 200.8% | 184.44K▲ 0% |
| Gross Margin % | 67.77% | 26.68% | -93.71% | -87.15% | 36.67% | 19.14% |
| Gross Profit Growth % | - | -79.06% | -167.56% | -5.65% | 200.83% | - |
| Operating Expenses | 1.9M | 1.43M | 1.54M | 4.93M | 9.94M | 8.1M |
| OpEx % of Revenue | 86.94% | 123.56% | 690.51% | 1945.64% | 1635.64% | - |
| Selling, General & Admin | 1.46M | 1.12M | 1.3M | 4.24M | 5.02M | 6.41M |
| SG&A % of Revenue | 66.84% | 96.12% | 584.08% | 1672.83% | 827.06% | - |
| Research & Development | 806.68K | 5.51M | 525.56K | 691.77K | 4.99M | 2.08M |
| R&D % of Revenue | 36.98% | 474.94% | 235.46% | 272.81% | 820.73% | - |
| Other Operating Expenses | -368.11K | -5.19M | -288K | 0 | -73.77K | -390.63K |
| Operating Income | -418.13K▲ 0% | -1.12M▼ 168.8% | -1.75M▼ 55.7% | -5.15M▼ 194.5% | -9.71M▼ 88.5% | -7.92M▲ 0% |
| Operating Margin % | -19.17% | -96.88% | -784.22% | -2032.78% | -1598.97% | -821.68% |
| Operating Income Growth % | - | -168.84% | -55.72% | -194.47% | -88.47% | - |
| EBITDA | -390.26K | -1.05M | -1.67M | -5.05M | -9.65M | -7.84M |
| EBITDA Margin % | -17.89% | -90.69% | -748.92% | -1993.2% | -1588.48% | -813.87% |
| EBITDA Growth % | - | -169.64% | -58.86% | -202.35% | -90.95% | 17.22% |
| D&A (Non-Cash Add-back) | 27.86K | 71.78K | 78.79K | 100.37K | 63.74K | 75.25K |
| EBIT | -369.04K | -1.09M | -2.19M | -1.53M | -7.95M | -7.97M |
| Net Interest Income | -2.68M | -3.17M | -3.99M | -2.29M | -7.91K | -6.14K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.68M | 3.17M | 3.99M | 2.29M | 7.91K | 6.14K |
| Other Income/Expense | -2.63M | -3.14M | -4.43M | 1.34M | 1.76M | -59.82K |
| Pretax Income | -3.05M▲ 0% | -4.26M▼ 39.8% | -6.18M▼ 45.0% | -3.81M▲ 38.3% | -7.96M▼ 108.6% | -7.98M▲ 0% |
| Pretax Margin % | -139.71% | -367.07% | -2767.5% | -1503.93% | -1309.37% | -827.88% |
| Income Tax | 1K | 1K | 500 | 250 | 250 | 1.31K |
| Effective Tax Rate % | -0.03% | -0.02% | -0.01% | -0.01% | -0% | -0.02% |
| Net Income | -3.03M▲ 0% | -4.25M▼ 40.1% | -6.18M▼ 45.4% | -3.77M▲ 39.1% | -7.95M▼ 111.0% | -7.98M▲ 0% |
| Net Margin % | -139.08% | -366.42% | -2769.49% | -1485.06% | -1308.01% | -827.8% |
| Net Income Growth % | - | -40.15% | -45.39% | 39.08% | -111.04% | -1.47% |
| Net Income (Continuing) | -3.05M | -4.26M | -6.18M | -3.81M | -7.96M | -7.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -569.29K | -576.26K | -572.32K | -72.04K | -80.59K | -83.26K |
| EPS (Diluted) | -0.52▲ 0% | -0.74▼ 42.3% | -1.07▼ 44.6% | -0.95▲ 11.2% | -18.55▼ 1852.6% | -2.17▲ 0% |
| EPS Growth % | - | -42.31% | -44.59% | 11.21% | -1852.63% | -127.71% |
| EPS (Basic) | -0.52 | -0.74 | -1.07 | -0.95 | -18.55 | - |
| Diluted Shares Outstanding | 5.78M | 5.78M | 5.78M | 3.96M | 454.58K | 3.68M |
| Basic Shares Outstanding | 5.78M | 5.78M | 5.78M | 3.96M | 454.58K | 3.68M |
| Dividend Payout Ratio | - | - | - | - | - | - |
SXTP Balance Sheet
60 Degrees Pharmaceuticals, Inc. (SXTP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 2.44M | 1.18M | 1.1M | 7.24M | 5.39M | 6.31M |
| Cash & Short-Term Investments | 191.7K | 115.4K | 264.87K | 2.14M | 3.39M | 4.12M |
| Cash Only | 191.7K | 115.4K | 264.87K | 2.14M | 1.66M | 4.12M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 1.73M | 0 |
| Accounts Receivable | 859.42K | 146.36K | 45.97K | 231.33K | 486.75K | 674.04K |
| Days Sales Outstanding | 143.8 | 46.04 | 75.16 | 332.99 | 292.41 | 184.11 |
| Inventory | 1.04M | 689.04K | 518.58K | 466.17K | 442.76K | 527K |
| Days Inventory Outstanding | 539.77 | 295.62 | 437.78 | 358.55 | 420.02 | 297.78 |
| Other Current Assets | 352.16K | 0 | 68.63K | 2.73M | 1.07M | 992.39K |
| Total Non-Current Assets | 163.18K | 216.85K | 198.2K | 541.18K | 373.07K | 380.13K |
| Property, Plant & Equipment | 73.41K | 107.61K | 33.95K | 71.28K | 149.81K | 227.75K |
| Fixed Asset Turnover | 29.72x | 10.78x | 6.58x | 3.56x | 4.06x | 5.30x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 80.23K | 109.24K | 164.25K | 227.26K | 157.08K | 152.38K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 9.55K | 0 | 0 | 242.65K | 66.18K | 88.23K |
| Total Assets | 2.61M▲ 0% | 1.39M▼ 46.5% | 1.3M▼ 6.9% | 7.78M▲ 500.0% | 5.76M▼ 26.0% | 6.69M▲ 0% |
| Asset Turnover | 0.84x | 0.83x | 0.17x | 0.03x | 0.11x | 0.17x |
| Asset Growth % | - | -46.53% | -6.91% | 500.04% | -26.01% | -67.88% |
| Total Current Liabilities | 1.43M | 635.47K | 23.92M | 2.84M | 1.66M | 2.2M |
| Accounts Payable | 1.38M | 588.68K | 758.67K | 506.21K | 1.01M | 1.39M |
| Days Payables Outstanding | 714.95 | 252.56 | 640.46 | 389.35 | 955.86 | 522.7 |
| Short-Term Debt | 0 | 0 | 21.14M | 8.77K | 8.77K | 8.77K |
| Deferred Revenue (Current) | 0 | 0 | 325K | 0 | 0 | 0 |
| Other Current Liabilities | 2.04K | 0 | 1.49M | 2.31M | 640.83K | 797.27K |
| Current Ratio | 1.70x | 1.85x | 0.05x | 2.55x | 3.25x | 3.25x |
| Quick Ratio | 0.98x | 0.77x | 0.02x | 2.39x | 2.98x | 2.98x |
| Cash Conversion Cycle | -31.38 | 89.1 | -127.52 | 302.19 | -243.42 | -40.81 |
| Total Non-Current Liabilities | 19.24M | 18.91M | 1.53M | 150.25K | 147.12K | 144.99K |
| Long-Term Debt | 15.92M | 18.74M | 1.27M | 150.25K | 147.12K | 144.99K |
| Capital Lease Obligations | 0 | 13K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.22M | 0 | 0 | 0 | 0 | -1 |
| Total Liabilities | 20.68M | 19.55M | 25.45M | 2.99M | 1.8M | 2.34M |
| Total Debt | 15.92M | 18.8M | 22.42M | 172.67K | 155.89K | 153.76K |
| Net Debt | 15.73M | 18.69M | 22.15M | -1.97M | -1.5M | -3.96M |
| Debt / Equity | - | - | - | 0.04x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | 0.51x |
| Interest Coverage | -0.16x | -0.35x | -0.44x | -2.25x | -1227.87x | -1297.95x |
| Total Equity | -18.07M▲ 0% | -18.15M▼ 0.5% | -24.15M▼ 33.0% | 4.8M▲ 119.9% | 3.96M▼ 17.6% | 4.35M▲ 0% |
| Equity Growth % | - | -0.46% | -33.02% | 119.87% | -17.57% | -108.87% |
| Book Value per Share | -3.13 | -3.14 | -4.18 | 1.21 | 8.70 | 1.18 |
| Total Shareholders' Equity | -17.5M | -17.58M | -23.58M | 4.87M | 4.04M | 4.43M |
| Common Stock | 799.7K | 4.98M | 239 | 10 | 57 | 410 |
| Retained Earnings | -18.38M | -22.63M | -28.82M | -32.58M | -40.53M | -46.45M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 80.45K | 75.83K | 73.71K | 135.56K | 135.47K | 144.04K |
| Minority Interest | -569.29K | -576.26K | -572.32K | -72.04K | -80.59K | -83.26K |
SXTP Cash Flow Statement
60 Degrees Pharmaceuticals, Inc. (SXTP) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -167.3K | -649.11K | -1.01M | -4.54M | -5.65M | -5.65M |
| Operating CF Margin % | -7.67% | -55.94% | -452.48% | -1791.56% | -929.61% | - |
| Operating CF Growth % | - | -287.99% | -55.6% | -349.8% | -24.33% | -2560.62% |
| Net Income | -3.05M | -4.26M | -6.18M | -3.77M | -7.96M | -7.98M |
| Depreciation & Amortization | 27.86K | 71.78K | 78.79K | 100.37K | 63.74K | 75.25K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 3.61M | 248.4K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 425.74K | 642.92K | 1.78M | -1.28M | -1.56M | 652.55K |
| Working Capital Changes | 2.43M | 2.9M | 3.31M | 405.36K | 192.72K | 186.81K |
| Change in Receivables | -660.28K | 713.06K | 100.4K | -185.37K | -255.42K | -350.21K |
| Change in Inventory | 190.78K | 312.23K | -52.94K | 212.75K | 23.41K | -319.65K |
| Change in Payables | 796.29K | -844.67K | 169.99K | -214.73K | 501.41K | 785.38K |
| Cash from Investing | -70.98K | -35.39K | -60.13K | -115.89K | -1.89M | 1.62M |
| Capital Expenditures | -70.98K | -3.07K | -60.13K | -57.62K | -103.77K | -84.75K |
| CapEx % of Revenue | 3.25% | 0.26% | 26.94% | 22.72% | 17.08% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -32.32K | 0 | -58.27K | -77.34K | 0 |
| Cash from Financing | 277.36K | 611.23K | 1.22M | 6.47M | 7.05M | 5.98M |
| Debt Issued (Net) | 277.36K | 611.23K | 1.1M | -961.11K | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 1000K | 1.92M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 116.71K | 981.35K | 10.96K | 85.05K |
| Net Change in Cash | -95.17K▲ 0% | -76.3K▲ 19.8% | 149.47K▲ 295.9% | 1.88M▲ 1156.2% | -483.13K▼ 125.7% | 815.09K▲ 0% |
| Free Cash Flow | -238.28K▲ 0% | -684.5K▼ 187.3% | -1.07M▼ 56.3% | -4.66M▼ 335.4% | -5.83M▼ 25.1% | -6.86M▲ 0% |
| FCF Margin % | -10.92% | -58.99% | -479.42% | -1837.26% | -959.42% | -711.94% |
| FCF Growth % | - | -187.27% | -56.34% | -335.36% | -25.12% | -59.22% |
| FCF per Share | -0.04 | -0.12 | -0.19 | -1.18 | -12.82 | -12.82 |
| FCF Conversion (FCF/Net Income) | 0.06x | 0.15x | 0.16x | 1.21x | 0.71x | 0.86x |
| Interest Paid | 0 | 0 | 2.19K | 179.12K | 8.77K | 0 |
| Taxes Paid | 1.25K | 750 | 1K | 1K | 2K | 0 |
SXTP Key Ratios
60 Degrees Pharmaceuticals, Inc. (SXTP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -78.48% | -181.58% | -183.49% |
| Return on Invested Capital (ROIC) | -157.67% | - | -928.58% | -276% | -276% |
| Gross Margin | 26.68% | -93.71% | -87.15% | 36.67% | 19.14% |
| Net Margin | -366.42% | -2769.49% | -1485.06% | -1308.01% | -827.8% |
| Debt / Equity | - | - | 0.04x | 0.04x | 0.04x |
| Interest Coverage | -0.35x | -0.44x | -2.25x | -1227.87x | -1297.95x |
| FCF Conversion | 0.15x | 0.16x | 1.21x | 0.71x | 0.86x |
| Revenue Growth | -46.81% | -80.76% | 13.6% | 139.61% | 135.78% |
SXTP Frequently Asked Questions
60 Degrees Pharmaceuticals, Inc. (SXTP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
60 Degrees Pharmaceuticals, Inc. (SXTP) reported $1.0M in revenue for fiscal year 2024. This represents a 56% decrease from $2.2M in 2020.
60 Degrees Pharmaceuticals, Inc. (SXTP) grew revenue by 139.6% over the past year. This is strong growth.
60 Degrees Pharmaceuticals, Inc. (SXTP) reported a net loss of $8.0M for fiscal year 2024.
Dividend & Returns
60 Degrees Pharmaceuticals, Inc. (SXTP) has a return on equity (ROE) of -181.6%. Negative ROE indicates the company is unprofitable.
60 Degrees Pharmaceuticals, Inc. (SXTP) had negative free cash flow of $6.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More SXTP
60 Degrees Pharmaceuticals, Inc. (SXTP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates